Early post-lung transplant calcineurin inhibitor management varies widely: An international survey.
Early post-lung transplant calcineurin inhibitor management varies widely: An international survey.
复制标题
肺移植后早期钙调神经磷酸酶抑制剂的管理差异很大:一项国际调查。
DOI:
10.1111/ctr.14510
复制
发表时间:
2022
影响因子:
2.1
通讯作者:
Shashaty,MichaelGS
中科院分区:
文献类型:
--
作者:
Farrell,ChristineL;Miano,ToddA;Griffiths,Stephen;Christie,JasonD;Diamond,JoshuaM;Shashaty,MichaelGS
Calcineurin inhibitors (CNI) are critical for preventing allograft rejection after lung transplantation, but have known nephrotoxic and other adverse effects. 1, 2 There are limited data and no consensus guidelines to inform dosing, target levels, and associated risks in the early post-transplant period, a timeframe when recipients may be particularly vulnerable to adverse CNI effects such as acute kidney injury (AKI). 3 We therefore conducted an anonymous international survey of clinicians, exempted by the University of Pennsylvania institutional review board, regarding CNI practices during the first 2 weeks after lung transplantation. From October-November 2020, we invited clinicians to participate via REDCap weblink posted to the International Society for Heart and Lung Transplantation (ISHLT) lung transplant and pharmacy discussion groups and the Lung Transplant Outcomes Group investigator listserv.Survey respondents (n= 77) were primarily pulmonologists and pharmacists from North America (Figure 1A). Tacrolimus was the initial CNI used by 73 (94.8%) respondents. Sixty-three (81.8%) reported use of induction agents (55 basiliximab, 5 antithymocyte globulin, 3 alemtuzumab) while 14 (18.2%) used none, similar to ISHLT Registry data. 4